The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.10 (6.667%)
Open: 1.55
High: 1.55
Low: 1.55
Prev. Close: 1.55
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Aston Martin CEO ups stake; Alkemy's lithium deal

Tue, 03rd Oct 2023 17:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Aston Martin Lagonda Global Holdings PLC - Gaydon, England-based luxury sports car manufacturer - Chief Executive Lawrence Stroll increases stake to 26% from 23% on October 3.

----------

Edinburgh Investment Trust PLC - Edinburgh-based investment trust - Liontrust Fund Partners LLP informs company that James de Uphaugh, the company's portfolio manager, will retire in February 2024. De Uphaugh will continue to manage the portfolio until February and will then be replaced as by Imran Sattar. As part of the succession, Sattar has been appointed deputy portfolio manager, replacing Chris Field who is due to retire from Liontrust in November. Other than the change of portfolio manager, there will be no change to the two investment objectives, strategy or the portfolio's key features, company says.

----------

DWF Group PLC - Manchester, England-based legal business with operations in North America - Announces the scheme which facilitates the bid by Inflexion Private Equity Partners LLP has become effective. The entire issued share capital of DWF is now owned or controlled by Inflexion. Shares in DWF have been suspended and are expected to be cancelled on October 4. As a result of the scheme becoming effective, DWF announces that: Teresa Colaianni, Samantha Duncan, Luke Savage, Jonathan Bloomer and Chris Sullivan have resigned as non-executive directors with effect from October 3. Further, Seema Bains and Michele Cicchetti have resigned as partner directors of the board with effect from October 3.

----------

Angus Energy PLC - UK-focused oil and gas development company - Reports gas volumes produced and sold from the Saltfleetby Field equalled 7.9 million therms in aggregate for the months of July, August and September, compared to 6.8 million therms produced and sold in the second quarter of this year. Notes third quarter production equates to an average of 2.6 million therms per month, up from 2.3 million therms per month in the second quarter, and against hedged volumes of 1.5 million therms per month for the third quarter, down from 1.75 million therms per month for the second quarter. Operational efficiency was 90% for the third quarter compared to 88% operational efficiency for the second quarter. The quarter included a planned full plant shut down for four days at the end of August for safety-critical maintenance and remedial work on one of the two compressor engines on the Saltfleetby site. Further, states work on the previously announced global refinance of the company's debt is well advanced, with a new reservoir model and production forecasts in the process of being finalized for lenders.

----------

Alkemy Capital Investments PLC - London-based company focused on acquisitions in the mining and technology metals sectors - Says Tees Valley Lithium has been shortlisted by a major automotive original equipment manufacturer as the preferred European lithium refiner for a portion of its lithium supply chain after extensive due diligence. Explains Tees Valley is a wholly owned UK subsidiary. Explains the due diligence focussed on Tees Valley Lithium's ability to import a lithium sulphate from its Port Hedland facility in Western Australia and the conversion into battery grade lithium hydroxide or carbonate at an internationally competitive price. Discussions are also advancing well with third parties, including other automotive OEMs, for access to Tees Valley Lithium's multi-train facilities, company states. Further, discussions are ongoing with two major trading groups to supply technical grade carbonate from South America and elsewhere to feed directly one of the trains at Tees Valley Lithium's Wilton refinery to produce battery grade lithium products on a toll treatment basis.

----------

City of London Investment Group PLC - investor in London-listed equities - Confirms Barry Aling will be retiring as non-executive chair at the annual general meeting on October 23. Says Rian Dartnell, a current non-executive director will become chair. Further, says Ted Sevick has been promoted to chief operating officer.

----------

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Confirms retail offer, launched on September 28, raised GBP118,337 taking total of fundraise to GBP5.1 million. The retail offer will result in the issue of a total of around 1.5 million shares.

----------

More News
26 May 2020 08:58

Shield Therapeutics names Hans Peter Hasler as next chairman

(Sharecast News) - Pharmaceutical group Shield Therapeutics named Hans Peter Hasler as non-executive chairman of the company on Tuesday.

Read more
1 May 2020 13:28

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

Read more
1 May 2020 09:55

Shield Therapeutics FY revenues impacted by milestone repayment

(Sharecast News) - Pharmaceuticals outfit Shield Therapeutics warned on Friday that full-year revenues would be lower than originally anticipated after it had to repay a sizeable milestone payment.

Read more
22 Apr 2020 15:13

UK EXECUTIVE CHANGE SUMMARY: Shield Therapeutics Replaces Founder

UK EXECUTIVE CHANGE SUMMARY: Shield Therapeutics Replaces Founder

Read more
18 Mar 2020 07:33

Shield Therapeutics Starts Independent Review Into Feraccru Study

Shield Therapeutics Starts Independent Review Into Feraccru Study

Read more
17 Mar 2020 15:17

Shield launches review after spotting flaw in 'Feraccru' study

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on the 'AEGIS-H2H' clinical trial on Tuesday, the data of which was primarily designed to be used in health economic analyses, pricing and reimbursement applications, as well as marketing purposes.

Read more
27 Jan 2020 15:07

Shield Therapeutics 2019 Revenue To Drop But Will Meet Expectations

Shield Therapeutics 2019 Revenue To Drop But Will Meet Expectations

Read more
27 Jan 2020 08:09

Shield Therapeutics details year of 'material progress'

(Sharecast News) - Drugs developer Shield Therapeutics told investors on Monday that 2019 had been a year of "material progress", with a key success being the recent Federal Drug Administration approval of its iron deficiency treatment, Feraccru/Accrufer.

Read more
8 Jan 2020 09:45

Shield Therapeutics Gets China Licence Agreement For Feraccru/Accrufer

Shield Therapeutics Gets China Licence Agreement For Feraccru/Accrufer

Read more
15 Aug 2019 14:28

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP134,000 In Shares

(Alliance News) - Shield Therapeutics PLC on Thursday said Chair James Karis acquired shares in the pharmaceutical company following a transaction on Tuesday.Karis purchased 75,000 shares a

Read more
7 Aug 2019 12:02

Shield Therapeutics Narrows Interim Losses Amid Expenses Fall

(Alliance News) - Drugmaker Shield Therapeutics said on Wednesday a payment from a commercial partner contributed to a sharp revenue rise in the first half of the year.In the six months to

Read more
3 Jun 2019 10:27

Teva Appeals Shield Therapeutics European Drug Patent Win

LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd has filed a notice of appeal on a decision regarding a Shield in a

Read more
26 Apr 2019 18:19

DIRECTOR DEALINGS: Shield Therapeutics Medical Chief Buys Shares

LONDON (Alliance News) - Shield Therapeutics PLC said on Friday that Chief Medical Officer Mark Sampson and his wife Julia have purchased shares in the company on Thursday.Mark bought at a

Read more
24 Apr 2019 12:22

Shield Therapeutics' Feraccru Granted Use Extension In Switzerland

LONDON (Alliance News) - Shield Therapeutics PLC said on Wednesday said the Swiss Agency for Therapeutic Products has approved the Feraccru product to treat iron deficiency in adults with or is to

Read more
17 Apr 2019 18:11

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP40,000 In Shares

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.